These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22335077)

  • 21. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 22. Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
    Marshall T
    BMJ; 2005 Nov; 331(7525):1144. PubMed ID: 16282417
    [No Abstract]   [Full Text] [Related]  

  • 23. Reducing the cost of rare disease drugs.
    Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
    [No Abstract]   [Full Text] [Related]  

  • 24. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

  • 25. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 26. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orphan drug pricing may warrant a competition law investigation.
    Roos JC; Hyry HI; Cox TM
    BMJ; 2010 Nov; 341():c6471. PubMed ID: 21081598
    [No Abstract]   [Full Text] [Related]  

  • 31. [Orphan drugs in France (2001-2005): access to information and characteristics].
    Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
    Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare diseases: the bane of modern society and the quest for cures.
    Azie N; Vincent J
    Clin Pharmacol Ther; 2012 Aug; 92(2):135-9. PubMed ID: 22814654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Orphan drugs: problem of public health and economic stakes].
    Brandissou S; Yagoubi N; Hasselot N
    Therapie; 1996; 51(6):647-53. PubMed ID: 9164001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 36. The problem of orphan drugs.
    Ferner RE; Hughes DA
    BMJ; 2010 Nov; 341():c6456. PubMed ID: 21081597
    [No Abstract]   [Full Text] [Related]  

  • 37. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rising cost of orphan drugs.
    Lancet Haematol; 2015 Nov; 2(11):e456. PubMed ID: 26686251
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of rare diseases.
    Walshe JM
    QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334
    [No Abstract]   [Full Text] [Related]  

  • 40. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.